893449-38-2 Usage
Uses
Used in Cancer Research:
PRL-3 INHIBITOR I is used as a research tool for studying the role of PRL-3 in cancer progression and metastasis. It helps in understanding the molecular mechanisms underlying the invasive properties of cancer cells and the potential of PRL-3 as a therapeutic target.
Used in Drug Development:
PRL-3 INHIBITOR I is used as a lead compound in the development of novel anti-cancer drugs. Its ability to sensitize PRL-3-expressing cancer cells to chemotherapeutics makes it a promising candidate for combination therapies to improve the efficacy of existing cancer treatments.
Used in Drug Screening:
PRL-3 INHIBITOR I is used as a screening agent to identify other potential inhibitors of PRL-3. This can help in the discovery of new compounds with improved potency, selectivity, and pharmacological properties for the treatment of cancer.
Used in Cell Biology Research:
PRL-3 INHIBITOR I is used as a cell-permeable benzylidene rhodamine to study the effects of PRL-3 inhibition on cellular processes such as cell migration, invasion, and adhesion. This can provide valuable insights into the role of PRL-3 in cancer cell behavior and the potential of targeting this enzyme for therapeutic intervention.
in vitro
prl-3 inhibitor, in a dose-dependent fashion, blocked the dephosphorylation of difmup by prl-3 and strongly suppressed the activity of prl-3 phosphatase in prl-3 overexpressing dld-1 colon tumor cells [dld-1 (prl-3)]. also, prl-3 inhibitor dose-dependently blocked the migration of dld-1 (prl-3) cells, however, it did not inhibit the proliferation of dld-1(prl-3) cells, suggesting that prl-3 inhibitor significantly blocked cell immigration and invasion without cytotoxicity [1].
IC 50
900 nm: blocks human phosphatase of regenerating liver 3 (prl-3) in vitro.
References
1) Ahn et al. (2006), Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors; Bioorg. Med. Chem. Lett., 16 2996
2) Min et al. (2013), Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells; Bioorg. Med. Chem. Lett., 23 3769
3) Zhao et al. (2011), PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy; PLoS One, 6(5) e19798
4) Tian et al. (2012), Phosphatase of regenerating liver-3 directly interacts with integrin β1 and regulates its phosphorylation at tyrosine 783; BMC Biochemistry, 13 22
Check Digit Verification of cas no
The CAS Registry Mumber 893449-38-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,3,4,4 and 9 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 893449-38:
(8*8)+(7*9)+(6*3)+(5*4)+(4*4)+(3*9)+(2*3)+(1*8)=222
222 % 10 = 2
So 893449-38-2 is a valid CAS Registry Number.
893449-38-2Relevant academic research and scientific papers
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells
Min, Garam,Lee, Su-Kyung,Kim, Hye-Nan,Han, Young-Min,Lee, Rhan-Hee,Jeong, Dae Gwin,Han, Dong Cho,Kwon, Byoung-Mog
, p. 3769 - 3774 (2013/07/27)
PRL-3, phosphatase of regenerating liver-3, plays a role in cancer progression through its involvement in invasion, migration, metastasis, and angiogenesis. We synthesized rhodanine derivatives, CG-707 and BR-1, which inhibited PRL-3 enzymatic activity wi
